Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-Current Deffered Revenue (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Non-Current Deffered Revenue for 10 consecutive years, with $176000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 61.23% to $176000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $176000.0 through Dec 2025, down 61.23% year-over-year, with the annual reading at $391000.0 for FY2025, 85.38% down from the prior year.
  • Non-Current Deffered Revenue hit $176000.0 in Q4 2025 for Vistagen Therapeutics, down from $336000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $2.7 million in Q1 2024 to a low of $176000.0 in Q4 2025.
  • Historically, Non-Current Deffered Revenue has averaged $981925.0 across 5 years, with a median of $432700.0 in 2022.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 91.1% in 2021 and later soared 801.34% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $276500.0 in 2021, then skyrocketed by 801.34% to $2.5 million in 2022, then plummeted by 86.93% to $325700.0 in 2023, then surged by 39.39% to $454000.0 in 2024, then crashed by 61.23% to $176000.0 in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for VTGN at $176000.0 in Q4 2025, $336000.0 in Q3 2025, and $221000.0 in Q2 2025.